Filter byLast updatedSelectAfterBeforeFrom - ToDateEnd DateCategoryHumanTopicCOVID-19MedicinesPaediatricsAdvanced therapiesAntimicrobial resistanceBiologicalsBiosimilarsBrexitCareersClinical trialsCompassionate useCompliance and inspectionsCorporateData on medicinesEarly accessFeesGeneric and hybrid medicinesGovernanceInnovationMaximum residue limitMedication errorMedicines for use outside the EUMedicine shortagesMpoxParallel distributionPharmacovigilanceProcurementProduct informationQuality of medicinesRare diseasesReferralsRegulatory and procedural guidanceResearch and developmentScientific adviceScientific guidelinesSMEVaccinesVeterinary limited marketsDiseases areaCancerCardiovascular diseasesDiabetesImmune-system diseasesNeurodegenerative diseasesViral diseasesHIV and AIDSTreatment of human immunodeficiency virus type 1 (HIV-1) infectionResponsible bodyCHMPPDCOPRACCATCMDhCOMPCVMPHMPCManagement BoardPatient safetyYesFiltersResults (5) RonapreveSort byLast update date (new to old)Last update date (old to new)A-ZZ-AETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-29 December 2022NewsHumanCOVID-19MedicinesCOVID-19: EMA recommends authorisation of antibody medicine Xevudy16 December 2021NewsHumanCOVID-19MedicinesCOVID-19: EMA recommends authorisation of two monoclonal antibody medicines12 November 2021NewsHumanCOVID-19MedicinesMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 202112 November 2021NewsHumanCOVID-19MedicinesEMA receives application for marketing authorisation for Ronapreve (casirivimab / imdevimab) for treatment and prevention of COVID-1911 October 2021NewsHumanCOVID-19Paediatrics
ETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-29 December 2022NewsHumanCOVID-19Medicines
COVID-19: EMA recommends authorisation of antibody medicine Xevudy16 December 2021NewsHumanCOVID-19Medicines
COVID-19: EMA recommends authorisation of two monoclonal antibody medicines12 November 2021NewsHumanCOVID-19Medicines
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 202112 November 2021NewsHumanCOVID-19Medicines
EMA receives application for marketing authorisation for Ronapreve (casirivimab / imdevimab) for treatment and prevention of COVID-1911 October 2021NewsHumanCOVID-19Paediatrics